SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...
Read More
Notice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...
Read More
Change of Director's Interest Notice
Appendix 3Y – Change of Director’s Interest Notice, is available to download.
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...
Read More
Changes of Director's Interest Notice
Appendix 3Y Change of Director’s Interest Notice Download PDF
Read More
Appendix 3B
New issue announcement, application for quotation of additional securities and agreement. Download...
Read More
Changes in Composition to Committeess
CLINUVEL PHARMACEUTICALS LTD today announced changes to the composition of its Audit...
Read More
CLINUVEL Appoints Non-Executive Director
CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Professor Jeffrey Rosenfeld as...
Read More
Chair’s Address to the Annual General Meeting
Melbourne, Australia, 20 November 2019 A MOMENTOUS ACHIEVEMENT Looking at the year...
Read More
Results of Meeting
Results of Annual General Meeting In accordance with Listing Rule 3.13.2...
Read More
Managing Director's AGM Presentation
Melbourne, Australia, 20 November 2019 “We are here today to reflect on...
Read More
Appendix 4C
CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...
Read More
TGA Priority Registration Pathway for SCENESSE
CLINUVEL PHARMACEUTICALS LTD today announced that the Australian Therapeutic Goods Administration (TGA)...
Read More